South Africa's competition watchdog launches a crucial investigation into pharmaceutical giants Novo Nordisk and Sanofi over ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio ... recently received approval in the EU for treating haemophilia A or B with inhibitors. Alhemo is not approved in the ...

Danish pharmaceutical company Novo Nordisk turned the market upside down when it launched Ozempic, a diabetes drug that ended ...

Vikrant Shrotriya, Corporate Vice President & Managing Director of Novo Nordisk India, during a session at India Today Conclave 2025, said that many celebrities may not want to admit to taking ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Vikrant Shrotriya, Corporate Vice President Managing Director of Novo Nordisk India, during a session on India Today Conclave ...

The European makers of Ozempic for diabetes and Cetaphil for dry skin said they would feel an impact from President Donald Trump’s threatened tariffs.

(Reuters) - A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular ...